591 results about "In vitro experiment" patented technology

The invention relates to application of a targeted inhibition circPDK1 reagent in preparation of an anti-esophageal cancer drug, and belongs to the field of biological medicines. The reagent for targeted inhibition of circPDK1 expression provided by the invention is shRNA or siRNA, and in-vivo and in-vitro experiments prove that the reagent can significantly inhibit circPDK1 expression and inhibit growth and migration of esophageal cancer tumor cells; after siRNA of targeted annular circPDK1 is packaged into efficient and low-toxicity LNP-siRNA, circPDK1 expression is specifically silenced, proliferation and migration of esophageal cancer tumors can be remarkably inhibited, and a basis is provided for clinical treatment and scientific research of esophageal cancer related circRNA.

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention relates to the field of molecular targeted therapy, and discloses an application of an SLC16A5 (MCT6) small-molecule inhibitor MCT6-Ai7-2 in preparation of a medicine for treating acute myeloid leukemia (AML). The inhibitor takes an SLC16A5 protein structure predicted by Alphafold as a target spot, and is obtained through compound database screening, molecular docking and druggability optimization. An in-vitro experiment proves that MCT6-Ai7-2 can remarkably inhibit proliferation of AML cell lines such as U937 and MOLM-13, induce cell apoptosis and retard a cell cycle, has an inhibiting effect on a primary AML patient specimen and is relatively low in toxicity to normal cells; in-vivo experiments show that the compound is effective and has good safety in AML model mice. In addition, the MCT6-Ai7-2 and the vinca can be combined to synergistically enhance the inhibition effect on vinca drug-resistant cells, and by reducing the expression of anti-apoptotic protein MCL-1, the activation of pro-apoptotic factors BIM and tBID is promoted to play a role. The invention provides a novel targeting drug and strategy for treatment of AML (especially drug-resistant or recurrent patients).

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

The invention relates to application of 1, 2, 3, 4, 6-O-pentagalloylglucose in preparation of a medicine for resisting cholestatic liver diseases, and belongs to the technical field of medicinal chemistry. The 1, 2, 3, 4, 6-O-pentagalloylglucose provided by the invention can be used for promoting bile acid excretion by reducing WDR6 protein expression. In-vivo and in-vitro experiments prove that the 1, 2, 3, 4, 6-O-pentagalloylglucose can be used for remarkably relieving the symptom of the cholestatic liver disease. In addition, the 1, 2, 3, 4, 6-O-pentagalloylglucose has no obvious toxic or side effect, and has no obvious influence on the liver function and the kidney function. The 1, 2, 3, 4, 6-O-pentagalloylglucose has a wide anti-cholestatic liver disease spectrum, and is suitable for various cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and the like.

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The invention discloses application of a CXCL14 combined immune checkpoint inhibitor in treatment of spinal glioma. The immune checkpoint inhibitor is selected from a PD-1 inhibitor or a combination of the PD-1 inhibitor and a CTLA4 inhibitor. In-vivo and in-vitro experiments prove that the CXCL14 combined with the PD-1 inhibitor, the CXCL14 combined with the PD-1 inhibitor and the CTLA4 inhibitor can be used for remarkably inhibiting the growth of mutant spinal glioma and have a remarkable synergistic effect. The invention provides a new strategy for treatment of spinal glioma, and is widely applied clinically.

The invention relates to a polypeptide capable of promoting tuft cell proliferation and application of the polypeptide in treatment of inflammatory bowel diseases, in particular to a polypeptide Sjp40-73 derived from schistosome egg protein, and the amino acid sequence of the polypeptide Sjp40-73 is SEQ ID NO.1. The invention further relates to a preparation method of the polypeptide Sjp40-73. The polypeptide can be obtained through methods such as genetic engineering expression or chemical synthesis. In-vitro experiments prove that the peptide can effectively increase the number of tuft cells of intestinal organs of mice; in-vivo experiments further prove that the peptide can relieve mouse inflammatory bowel diseases and can improve corresponding inflammations. The polypeptide prepared by the invention can be applied to medicines, health-care products or food additives for preventing and treating inflammatory enteritis.

The invention discloses application of sodium butyrate in preparation of a medicine for relieving brain injury caused by gas explosion, the sodium butyrate regulates nerve cell ferroptosis through a JNK / P38 MAPK pathway to relieve the brain injury caused by gas explosion, firstly, an animal model of rat brain injury caused by gas explosion is established, and the relation between NaB and brain tissue neuron injury is intervened and observed by applying NaB; secondly, a shock wave physiotherapy instrument is used for impacting a co-culture system of three cells of CTX, H19-7 and GMI-R to simulate explosion to construct an in-vitro experimental model, P38, ERK and Fer-1 inhibitors are adopted for intervention, iron metabolism, ferroptosis and MAPK signal channel factor changes are observed from the cell and molecular level, a mechanism for inhibiting ferroptosis through a related cascade signal channel mediated by NaB-mediated intestinal-brain axis regulation and control is clarified, and the effect of inhibiting ferroptosis is achieved. And a theoretical basis is provided for further explaining the action mechanism of the gas explosion brain injury.

The invention discloses a pressure-controlled bovine bone collagen active peptide, and belongs to the field of food. A potential ACE inhibitory peptide is rapidly screened through a bioinformatics method, the ACE inhibitory activity of the bovine bone collagen peptide is verified in combination with an in-vitro experiment, IC50 values of the screened bovine bone collagen active peptides LGALPGF, VFPGLL and AAAALGPW to ACE are 32.07 mu M, 40.41 mu M and 77.68 mu M respectively, and the peptide with the sequence is proved to have a good antihypertensive function.

The invention discloses a genetically engineered probiotic composition for expressing ADH (adenosine dihydrogenase) and ALDH (aldehyde dehydrogenase) and application of the genetically engineered probiotic composition in hangover alleviating and liver protection. The genetically engineered probiotic composition (such as EcN.1917-ADH and EcN.1917-ALDH) is constructed by introducing genes of alcohol dehydrogenase (ADH, NCBI (National Center for Biotechnology Information) Gene ID: 855349) and acetaldehyde dehydrogenase (ALDH, NCBI Gene ID: 855206) of saccharomyces cerevisiae into probiotics (such as escherichia coli). The engineering bacterium shows remarkable ethanol, acetaldehyde and endurance capacity in an in-vitro experiment, and the ethanol degradation rate is remarkably higher than that of a wild type strain; a mouse drunkenness model verifies that drunkenness and death caused by drinking can be reduced through pretreatment, drunkenness tolerance time is remarkably prolonged, and movement coordination disorder caused by alcohol can be improved. The strain can effectively promote alcohol metabolism and relieve alcoholic liver injury, and a new candidate strain is provided for development of a hangover-alleviating and liver-protecting viable bacterial preparation.

The invention provides a traditional Chinese medicine preparation for treating allergic rhinitis and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is prepared from radix asteris, schizonepeta spike, cynanchum paniculatum, perillaseed, spina gleditsiae, cottonrose hibiscus leaf, magnolia flower, semen brassicae, cortex lycii radicis, dendrobe, oroxylum indicum and rhodomyrtus tomentosa; an in-vitro experiment shows that the traditional Chinese medicine preparation can remarkably inhibit the activity of hyaluronidase, also can inhibit the release of beta-HEX in an RBL-2H3 cell degranulation model, reduces the HIS level in a cell supernatant, and effectively improves the morphological abnormality caused by degranulation of RBL-2H3 cells; in-vivo experiments show that the traditional Chinese medicine preparation can significantly reduce behavioral scores of mice suffering from allergic rhinitis, inhibit expression of inflammatory factors TNF-alpha, serum Ig E and OVE-sIg E levels and HA concentration, reduce histopathologic changes caused by allergic rhinitis, effectively repair immune injuries of nasal mucosa of the mice and improve the curative effect of the mice. And a safe and effective new strategy is provided for the treatment of allergic rhinitis.

The invention discloses an application of a pharmaceutical composition of erianin (ERI) and sorafenib (SOR) in preparation of an anti-liver cancer drug. The invention further discloses a pharmaceutical composition which comprises ERI and SOR, and the specific molar ratio of ERI to SOR is optimized and determined through an in-vitro experiment. The composition is developed based on multi-mode screening (network pharmacology prediction, molecular docking and molecular dynamics simulation) of STAT3 targets, and in-vitro experiments prove that the composition has synergistic anti-tumor activity and can be used for preparing anti-liver cancer drugs. The invention further discloses a development method of the ERI-SOR composition integrated with multi-mode computational simulation. Experiments prove that ERI and SOR both show a remarkable synergistic effect (combination index (CI) lt, 1) at the concentration of 0.5-16 [mu] M, CI at the optimal ratio (1: 1, 4 [mu] M + 4 [mu] M) reaches 0.617, the cell proliferation inhibition effect is remarkable compared with that of a single drug, and the excellent synergistic effect is shown.

The present application provides a kind of Radix Polygoni Multiflori active ingredient separation and purification process, belong to plant extraction technical field.The present application separation and purification process includes: Radix Polygoni Multiflori ethanol ultrasonic extraction, activated carbon adsorption, HPD-100 macroporous resin purification, membrane filtration, ultrafiltration, reduced pressure concentration and crystallization step, can efficiently extract Radix Polygoni Multiflori extract with high 5 alpha-reductase inhibitory activity.After compounding with the extract of Euonymus alatus obtained by specific microbial fermentation, the anti-hair loss effect can be significantly enhanced.The in vitro experimental results show that the Radix Polygoni Multiflori extract and the extract of Euonymus alatus both have significant 5 alpha-reductase inhibitory activity.The present application can effectively promote hair growth and improve hair loss, and the effect is close to the positive control drug.The present application process is stable, high in purity, strong in activity, suitable for industrial production, and has good market application prospect.

The invention discloses a carbamoyl-substituted diarylethene derivative as well as a preparation method and application thereof, and the preparation method comprises the following steps: reacting R-substituted 3-bromo-2-hydroxybenzaldehyde with an arylmethyl triphenylphosphonium bromide compound or an aryl acetic acid compound to obtain an intermediate A; then the intermediate A and cuprous cyanide are subjected to a heating reaction in N, N-dimethylformamide and nitrogen atmosphere, and an intermediate B is obtained; and finally, heating the intermediate B, acetaldoxime and indium trichloride in toluene for reaction to obtain the carbamoyl-substituted diarylethene derivative. The carbamoyl-substituted diarylethene derivative disclosed by the invention has a remarkable effect in an in-vitro anti-tumor activity test, particularly has excellent anti-proliferation ability to human BRCA mutant tumor cells, and can be used for preparing medicines for treating PARP-1 activity abnormity related diseases. The synthesis route is simple, the cost is low, and large-scale implementation is facilitated.

The invention discloses application of a neutralizing antibody of oncostatin M in preparation of a medicine for treating bronchial pulmonary dysplasia. The application proves that the intrauterine inflammation can cause BPD-like lung lesion to the filial generation mouse, and the OSM expression level in the mouse lung tissue one day after the intrauterine inflammation filial generation is grown is obviously higher than that of a control group; the OSM level of the BPD group is higher than that of the non-BPD group in the umbilical blood sample of the premature infant; in-vitro experiments show that the OSM treatment can cause lung epithelial cell injury; by dripping a recombined OSM neutralizing antibody into the nose of a newborn mouse, down-regulation of the OSM level in the lung of the mouse is realized, filial generation lung injury induced by the intrauterine inflammation can be repaired, and the OSM can be used as a treatment target of the BPD caused by the intrauterine inflammation.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

The invention provides a nutrition enhancer beneficial to bone health of middle-aged and elderly people, a preparation method of the nutrition enhancer and application of the nutrition enhancer in preparation of medial care food, and belongs to the field of nutritious food. The nutrient supplement comprises a plant fermentation product, osteopontin peptide, collagen peptide, N-acetylglucosamine and calcium, vitamins and mineral substances can be added, and the plant fermentation product is obtained by performing anaerobic fermentation on rhizoma drynariae and chestnuts through a complex microbial inoculant composed of lactobacillus reuteri and bifidobacterium longum subsp. Longum; the collagen peptide is prepared by performing enzymolysis on bovine bones through alkaline protease and flavourzyme; the hydrogel is prepared by adopting a sodium alginate-calcium chloride-carboxymethyl chitosan micro-capsule embedding process. An in-vitro experiment shows that the nutrition enhancer can remarkably promote osteoblast proliferation, differentiation and mineralization; animal experiments show that the bone mineral density of osteoporosis model mice can be effectively improved. The nutrition enhancer disclosed by the invention is suitable for preparing care food and bone health products, and has a remarkable effect of improving bone health of middle-aged and elderly people.

The application discloses application of total flavones of chrysanthemum morifolium ramat and metabolites thereof in preparation of uric acid-lowering or liver and kidney protecting drugs or health care products. The total flavones of chrysanthemum morifolium ramat contain various flavone compounds. In a hyperuricemia model mouse, the total flavones of chrysanthemum morifolium ramat can significantly reduce blood uric acid level, and has a significant protective effect on liver and kidney, and the effect is achieved by inhibiting the activity and expression of xanthine oxidase and adenosine deaminase in the liver, and regulating the expression of uric acid related transporters in the kidney. Meanwhile, metabolites of the total flavones of chrysanthemum morifolium ramat, luteolin-7-O-glucuronide and apigenin-7-O-glucuronide, can also play a pharmacological role in the mouse body. In vitro experiments and mouse primary hepatocytes further prove that luteolin-7-O-glucuronide and apigenin-7-O-glucuronide have an inhibiting effect on the activity and expression level of xanthine oxidase. The application widens the application range of traditional Chinese medicinal materials, and provides a new direction for development of efficient and low-toxic uric acid-lowering and anti-gout drugs or health care products.

The invention belongs to the field of biomedical materials and tissue engineering, and particularly relates to an injectable mineralized collagen bone repair composite material loaded with stem cell recruitment factors and osteogenic induction factors and a preparation method of the injectable mineralized collagen bone repair composite material. The composite material is composed of 50%-53% of mineralized collagen matrix particles, 15%-20% of SDF-1alpha loaded heparinized gelatin microspheres, 15%-20% of BMP-2 loaded PDA coated mesoporous silica particles, 8%-10% of an NHS-PEG-NHS cross-linking agent and 4%-6% of glycerin. The composite material can realize time-space sequential regulation and control of'collection first and then differentiation '; a bionic bone matrix microenvironment is provided through the mineralized collagen matrix; the problems of two-factor release conflict and stability are solved; in-vitro experiments show that the material can significantly promote stem cell migration and osteogenic differentiation, and animal experiments prove that the material can recover 82-88% of mechanical properties of bone defect parts. The invention solves the technical problems of insufficient stem cell collection, low osteogenic differentiation efficiency and uncontrollable factor release of the existing bone repair material.

The invention belongs to the technical field of red date polysaccharide application, and discloses application of red date polysaccharide in preparation of a product for enhancing immune regulation ability, and the product is chewable tablets or capsules. The chewable tablet or capsule takes red date polysaccharide as a main active ingredient, and active ingredients and / or preparation auxiliary materials which do not influence the red date polysaccharide are added; the preparation process conditions of the red date polysaccharide are determined through single factor and response surface experiments, and in-vitro experiments verify that the red date polysaccharide can enhance the proliferation ability and phagocytic ability of macrophages, so that the immunoregulation ability can be enhanced, and the components are safe.

The invention provides an anti-aging composition as well as a preparation method, a skin care product and application thereof. The anti-aging composition is prepared from a C6-C3-C6 skeleton compound, cationic amino acid and beta-alanyl hydroxyprolyl diaminobutyric acid benzylamine. The C6-C3-C6 structural compound is natural plant extracts such as quercetin, baicalin and the like, and has excellent oxidation resistance and high safety. Cell and in-vitro experiments prove that the combined action of the three components can effectively reduce the generation of reactive oxygen species (ROS) and enhance the anti-inflammatory action, thereby delaying the cell senescence process. On the basis, carbon dioxide is injected into the anti-aging composition, so that the anti-oxidation and anti-inflammatory capacities of the anti-aging composition are further improved. In addition, the preparation process of the anti-aging composition is simple, the safety and the anti-aging performance of the anti-aging composition are evaluated through various cell experiments and human body trials, and the anti-aging composition is suitable for human skin and can be widely added into various skin care products such as face cream, emulsion and essence.

The invention discloses an application of 4-octyl itaconic acid (4-OI) in preparation of a medicine for improving pulmonary arterial hypertension (PAH). In-vivo experiments show that 4-OI can significantly reduce pulmonary vascular wall thickening and collagen deposition of a PAH rat model, and effectively improve PAH and vascular remodeling. In-vitro experiments further reveal that 4-OI reduces endoplasmic reticulum stress (ERS) by inhibiting a PERK-eIF2alpha pathway, further blocks SM22 dependent smooth muscle cell phenotypic transformation and endothelial-mesenchymal transformation (EndMT) processes, finally inhibits vascular remodeling, and plays a role in treating PAH. The three key pathological processes of ERS, EndMT and vascular remodeling are closely linked, a new perspective is provided for deeply understanding the correlation among oxidative stress, endothelial dysfunction and vascular structure change in PAH, meanwhile, a theoretical foundation is laid for developing PAH and vascular remodeling accurate treatment drugs, and clinical transformation value is achieved.

The invention belongs to the technical field of biomedical materials, and particularly relates to astragaloside-loaded conductive hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: uniformly mixing a methylacrylic anhydride gelatin aqueous solution with an organic solvent solution of astragaloside, and carrying out ultraviolet light cross-linking curing to form methylacrylic anhydride gelatin / astragaloside hydrogel; soaking the obtained hydrogel in hydrochloric acid containing a free radical initiator; then soaking and polymerizing in an aniline ethanol solution; and soaking and purifying to obtain the methylacrylic anhydride gelatin-polyaniline conductive hydrogel loaded with astragaloside. In-vitro experiments prove that the compound has a certain anti-inflammatory effect, can induce neural stem cells to be directionally differentiated into neurons and oligodendrocytes, and is beneficial to promoting nerve regeneration and myelin sheath formation; finally, in-vivo experiments prove that the composition can improve the athletic ability and tissue function recovery of SCI rats, and has a good application prospect.

Pulse wave velocity (PWV) is a measure of arterial stiffness and a cardiovascular disease risk factor. Accurate PWV estimation is difficult due to complex arterial dynamics, such as longitudinal motion and natural tissue oscillations. This present disclosure relates to a robust, motion-resistant PWV estimation framework including: 1) tracking and compensating for arterial longitudinal wall motions, 2) suppressing undulating arterial motion via common mode rejection, and 3) enhancing differential signals to extract wall expansion. In vitro experiments with induced lateral motion indicate the framework's PWV estimates (6.19±0.33 m / s) closely matched reference values (6.26±0.12 m / s; error: 1.1%), outperforming methods without motion compensation (4.46±1.78 m / s; error: 28.8%). In vivo trials with five healthy subjects showed an average PWV of 4.18±0.56 m / s using the motion-resistant method, compared to 2.54±0.95 m / s without motion compensation (p<0.005). This framework enhances PWV estimation reliability, offering clinical potential for better arterial stiffness assessment and cardiovascular risk stratification.

The invention provides a composition for reducing blood pressure, blood fat, blood sugar and uric acid and a preparation method thereof, the composition takes nine kinds of vegetable fat such as acer truncatum seed oil, tomato seed oil and the like as core raw materials, a composite antioxidant, phytosterol and xylooligosaccharide are supplemented, multiple-effect synergy is realized through scientific proportioning, and in the preparation process, the composition is free of toxic and side effects. And by adopting a step-by-step stirring technology, a nitrogen protection technology and a gradient ultrasonic homogenization technology, the biological activity of each component is effectively maintained. A plurality of in-vitro experiments and animal models verify that the composition can significantly regulate blood pressure, blood fat, blood sugar and uric acid levels through the synergistic effect of the raw materials. The raw materials are natural, the active ingredients are completely reserved, and the efficacy is stable, so that the functional health-care product has a wide application prospect in the field of functional health-care product development.

The invention provides an application of a CGRP inhibitor in preparation of a medicine for treating myocardial infarction or heart failure, relates to the technical field of biomedicine, and has the technical key points that the invention provides the CGRP inhibitor Rimegepant and provides an effect of the CGRP inhibitor Rimegepant in myocardial infarction and heart failure, and the CGRP inhibitor Rimegepant can be used for preparing a medicine for treating myocardial infarction or heart failure. The myocardial infarction and / or heart failure model is constructed through left anterior descending branch coronary artery ligation. In-vitro experiments verify that the expression of the CGRP receptor protein in the heart of a mouse after heart failure is increased, and prove that the CGRP inhibitor Rimegeant can effectively inhibit the expression of the CGRP receptor protein, and further research is carried out, so that a potential treatment strategy is provided for drug research and development. The in-heart CGRP receptor inhibitor can obviously relieve the myocardial infarction and / or heart failure course of mice, and down-regulate the protein expression of the CGRP receptor at the same time.

The application discloses application of a compound ZML1 in preparation of a medicine for treating acute drug-induced liver injury. Through in-vivo and in-vitro experiments, it is found that ZML1 can reverse acute liver injury only by acting for several hours, for example, restoring normal morphology of hepatocytes, reducing lipid deposition, rapidly improving damage performance of various transaminases and the like. The treatment effect of the compound ZML1 of the application on various liver injury indexes is superior to that of existing liver-protecting medicines, especially in improving lipid deposition of hepatocytes, and the compound ZML1 shows more excellent curative effect. Therefore, ZML1 has excellent drug property in treating acute drug-induced liver injury and protecting liver, and thus has a wide application prospect.

This invention relates to the fields of molecular biology and biomedicine, and discloses siRNA for the expression of the *Schistosoma japonicum* Hsc20 gene and its applications. The siRNA contains a nucleotide sequence that hybridizes to a target sequence of the *Schistosoma japonicum* Hsc20 gene, wherein the target sequence is selected from the sequences shown in SEQ ID NO. 1-SEQ ID NO. 4. The siRNA specifically inhibiting the expression of the *Schistosoma japonicum* Hsc20 gene provided by this invention can be used to interfere with the transcription and expression of the *Schistosoma japonicum* Hsc20 gene and the growth and development of *Schistosoma japonicum*. In vitro experiments have confirmed that the siRNA provided by this invention can efficiently silence the *SjHsc20* gene; and in vivo RNA interference experiments in mice show that this siRNA can induce 50.62% (…) P The insect reduction rate was <0.05% and 44.29% ( P A liver oocyte reduction rate of <0.01% is suitable for preparing drugs to treat schistosomiasis.

The invention provides a non-invasive tissue fluid lactic acid dynamic monitoring method. The method comprises the following steps: establishing a relation model of epidermal and subcutaneous lactic acid concentrations; steady-state current values under different epidermal lactic acid concentrations are obtained through in-vitro experiments, and then the function relation between the steady-state current values and the epidermal lactic acid concentrations is obtained; net current values under different subcutaneous lactic acid concentrations are obtained through human body experiments, a function relationship between the net current values and the subcutaneous lactic acid concentrations is established, and the function relationship can be used for a subsequent transdermal extraction detection process; substituting the measured epidermal lactic acid concentration into a relation model of epidermal and subcutaneous lactic acid concentrations to obtain an accurate concentration value of tissue fluid lactic acid monitoring; according to the method, in the dynamic real-time monitoring process of the lactic acid concentration of the tissue fluid, the concentration of the lactic acid extracted from the epidermis measured by the lactic acid sensor can be converted into the real-time and accurate lactic acid concentration of the subcutaneous tissue fluid, and rapid, painless, infection-free and continuous monitoring of the lactic acid level of the subcutaneous tissue fluid can be achieved.